American Thyroid Association Satellite Symposium: The Spectrum of Thyroid Cancer, From Surveillance to Systemic Therapy

Friday, March 16, 2018
11:15 AM – 5:30 PM
McCormick Place West, Chicago, Illinois

PLEASE REGISTER THEN CLICK "START" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.

Target Audience

This continuing medical education activity should be of substantial interest to the community of endocrinologists, internists, surgeons, basic scientists, nuclear medicine scientists, pathologists, trainees, nurses, physician assistants, other health care professionals and the general public who wish to broaden and update their knowledge on hypothyroidism.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Understand how the therapy of hypothyroidism has evolved since the first use of thyroid gland preparations
  • Describe how TSH references intervals may vary for different populations and understand the impact of TSH values on outcomes, morbidity, and mortality
  • List the factors other than serum TSH values, such as T3 levels and polymorphisms in TH transporters and deiodinases, that may potentially provide information about the thyroid status of patients
  • Describe the potential benefits and risks of combination therapy, and weigh these factors in order to determine whether combination therapy should be offered to patients with hypothyroidism
  • Review areas with significant knowledge gaps, such as whether measuring additional thyroid analytes beyond TSH and FT4 is helpful, and whether diet/dietary supplements impact thyroid function
  • Describe how patient-centered outcomes might be incorporated into the management of patients with hypothyroidism
  • Appreciate the patient perspective during the treatment of hypothyroidism

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)

You may also be interested in

Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer - Webcast

OVERVIEW

Patients with radioactive iodine-refractory thyroid cancer (RAIR-DTC) have poor prognoses and, until recently, there were no effective targeted systemic therapies available for RAIR-DTC.
Activity summary
Available credit: 
  • 4.25 ABIM MOC
  • 4.25 AMA PRA Category 1 Credits™
  • 4.25 CME Certificate of Participation
  • 4.50 RCP MOC
Course opens: 
03/12/2018
Course expires: 
12/31/2018
Rating: 
0
Program Co-Chair 
Manisha H. Shah, MD
The Ohio State University, Columbus, Ohio
 
R. Michael Tuttle, MD
Memorial Sloan-Kettering Cancer Center, New York, New York
 
Faculty
Kenneth D. Burman, MD
MedStar Washington Hospital Center, Washington, DC
 
,David S. Cooper, MD
Johns Hopkins University School of Medicine, Baltimore, Maryland
 
Charles H. Emerson, MD
University of Massachusetts School of Medicine, Worchester, Massachusetts
 
Thomas J. Giordano, MD, PhD
University of Michigan, Ann Arbor, Michigan
 
Elizabeth Gardner Grubbs, MD
The University of Texas M. D. Anderson Cancer Center, Houston, Texas
 
Stephanie L. Lee, MD, PhD
Boston University Medical Center, Boston, Massachusetts
 
Virginia A. LiVolsi, MD
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
 
Lilah F. Morris-Wiseman, MD
Banner University Medical Center, Tucson, Arizona
 
Mara Yvonne Roth, MD
University of Washington, Seattle, Washington
 
Mona M. Sabra, MD
Memorial Sloan-Kettering Cancer Center, New York, New York
 
Wendy Sacks, MD
Cedars-Sinai Medical Center, Los Angeles, California
 
Carmen C. Solorzano, MD
Vanderbilt University, Nashville, Tennessee
 
Ralph P. Tufano, MD, MBA, FACS
Johns Hopkins University School of Medicine, Baltimore, Maryland
 
Program Committee Member
James D. Brierley, MB
Princess Margaret Hospital, Toronto, Ontario, Canada

Douglas Van Nostrand, MD
MedStar Washington Hospital Center, Washington, DC
 
Lori J. Wirth, MD
Massachusetts General Hospital

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The ATA Guidelines Satellite Symposium faculty reported relevant financial relationship(s):
Thomas J. Giordano, MD, PhD: Consultant, Rosetta Genomics
Manisha H. Shah, MD: Consulting, LOXO, Novartis; Primary Investigator, Merck, LOXO, Eisai
R. Michael Tuttle, MD: Consultant, Eisai, Genzyme, Sanofi, Bayer

The ATA Guidelines Satellite Symposium faculty reported no relevant financial relationship(s) during the content development process for this activity:
Charles H. Emerson, MD, Douglas Van Nostrand, MD, Mona M. Sabra, MD, Mara Yvonne Roth, MD, Wendy Sacks, MD, Carmen C. Solorzano, MD, Lilah F. Morris-Wiseman

The ATA Guidelines Satellite Symposium Program Committee member reported no relevant financial relationship (s):
James D. Brierley, Lori J. Wirth, MD

The ATA 2018 Satellite Symposium Program Committee members reported relevant financial relationship(s) during the content development process for this activity:
Virginia A. LiVolsi, MD: Consultant, Veracyte, inc

The following Endocrine Society Special Programs Committee member who reviewed content for this activity reported financial relationships:  
Giuseppe Barbesino, MD: Spouse, employee of Genzyme
 

The following SPC Committee members reported financial relationships:
Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexcom, Novo Nordisk, Trividia Health
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Natalie Cusano, MD: Research Support, Shire; Speaker, Shire
Joan Han, MD: Research Support, Rhythm Pharmaceutical
Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Merck, Radius Health;
Speaker, Amgen, Eli Lilly & Company, Radius Health, Shire
Alan Kelly, MD: Speaker, Eli Lilly
Jonathan Purnell, MD: Advisor, Novo Nordisk
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The following SPC members reported no relevant financial relationships:  
Amy Rothberg, MD, Susmeeta Sharma, MD

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical ed ucation for physicians. 

The Endocrine Society has achieved Accreditation with Commendation. 

The Endocrine Society designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™ and 4.25 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Review your ABIM Diplomate ID Number(s)

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM) or American Board of Pediatrics (ABP), you must:

  1. Provide your board-certification information in your educational profile.  Your profile currently contains the following board ID numbers (must be logged in to view):

    Your ABIM Number: [current-user:profile-profile:field-number-abim]*

    *If your ABP or ABIM number is blank or incorrect as shown above, please click the Update Profile button below to add or correct your profile.

  2. Update Profile

Available Credit

  • 4.25 ABIM MOC
  • 4.25 AMA PRA Category 1 Credits™
  • 4.25 CME Certificate of Participation
  • 4.50 RCP MOC

Accreditation Period

Course opens: 
03/12/2018
Course expires: 
12/31/2018